130 related articles for article (PubMed ID: 2559191)
1. Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852.
Friedman DI; Amidon GL
J Pharm Sci; 1989 Dec; 78(12):995-8. PubMed ID: 2559191
[TBL] [Abstract][Full Text] [Related]
2. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril.
Friedman DI; Amidon GL
Pharm Res; 1989 Dec; 6(12):1043-7. PubMed ID: 2560181
[TBL] [Abstract][Full Text] [Related]
3. Suitability of enalapril as a probe of the dipeptide transporter system: in vitro and in vivo studies.
Morrison RA; Chong S; Marino AM; Wasserman MA; Timmins P; Moore VA; Irwin WJ
Pharm Res; 1996 Jul; 13(7):1078-82. PubMed ID: 8842049
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells.
Thwaites DT; Cavet M; Hirst BH; Simmons NL
Br J Pharmacol; 1995 Mar; 114(5):981-6. PubMed ID: 7780654
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.
Sica DA; Cutler RE; Parmer RJ; Ford NF
Clin Pharmacokinet; 1991 May; 20(5):420-7. PubMed ID: 1652404
[TBL] [Abstract][Full Text] [Related]
6. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
[TBL] [Abstract][Full Text] [Related]
7. Hypotensive effect of a phosphorus-containing novel angiotensin converting enzyme inhibitor, (S)-1-[6-amino-2[[hydroxy(4-phenylbutyl)phosphinyl] oxy]-1-oxohexyl]-L-proline (SQ 29,852) in conscious hypertensive dogs.
Ohara N; Takizawa M; Yokota S; Ogawa N; Katsumura H; Ono H
J Pharmacobiodyn; 1992 Jun; 15(6):267-76. PubMed ID: 1432566
[TBL] [Abstract][Full Text] [Related]
8. (Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L -proline a novel orally active inhibitor of ACE.
Karanewsky DS; Badia MC; Cushman DW; DeForrest JM; Dejneka T; Loots MJ; Perri MG; Petrillo EW; Powell JR
J Med Chem; 1988 Jan; 31(1):204-12. PubMed ID: 3336020
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of angiotensin converting enzyme inhibition in tissues following oral lisinopril: studies in the rat using quantitative radioinhibitor binding.
Jackson B; Cubela R; Sakaguchi K; Johnston CI
Clin Exp Pharmacol Physiol; 1987 Apr; 14(4):343-7. PubMed ID: 2822313
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine.
McLean AJ; Drummer OH; Smith HJ; Froomes P; McNeil JJ
J Hum Hypertens; 1989 Jun; 3 Suppl 1():147-51. PubMed ID: 2550637
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function.
Hayes PC; Plevris JN; Bouchier IA
J Hum Hypertens; 1989 Jun; 3 Suppl 1():153-8. PubMed ID: 2550638
[TBL] [Abstract][Full Text] [Related]
12. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.
Mojaverian P; Rocci ML; Vlasses PH; Hoholick C; Clementi RA; Ferguson RK
J Pharm Sci; 1986 Apr; 75(4):395-7. PubMed ID: 3014110
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril.
Swaan PW; Stehouwer MC; Tukker JJ
Biochim Biophys Acta; 1995 May; 1236(1):31-8. PubMed ID: 7794953
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunoassay for the quantitation of lisinopril and enalaprilat.
Worland PJ; Jarrott B
J Pharm Sci; 1986 May; 75(5):512-6. PubMed ID: 3016233
[TBL] [Abstract][Full Text] [Related]
15. Buccal absorption of enalapril and lisinopril.
McElnay JC; Al-Furaih TA; Hughes CM; Scott MG; Elborn JS; Nicholls DP
Eur J Clin Pharmacol; 1998 Oct; 54(8):609-14. PubMed ID: 9860147
[TBL] [Abstract][Full Text] [Related]
16. Stability and in vitro absorption of captopril, enalapril and lisinopril across the rat intestine.
Zhou XH; Li Wan Po A
Biochem Pharmacol; 1994 Mar; 47(7):1121-6. PubMed ID: 8161340
[TBL] [Abstract][Full Text] [Related]
17. Distribution of the dipeptide transporter system along the gastrointestinal tract of rats based on absorption of a stable and specific probe, SQ-29852.
Marino AM; Chong S; Dando SA; Kripalani KJ; Bathala MS; Morrison RA
J Pharm Sci; 1996 Mar; 85(3):282-6. PubMed ID: 8699329
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ.
Sinko PJ; Amidon GL
Pharm Res; 1988 Oct; 5(10):645-50. PubMed ID: 3244617
[TBL] [Abstract][Full Text] [Related]
19. (Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme. 2. Terminal amino acid analogues of (S)-1-[6-amino-2 [[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline.
Karanewsky DS; Badia MC; Cushman DW; DeForrest JM; Dejneka T; Lee VG; Loots MJ; Petrillo EW
J Med Chem; 1990 May; 33(5):1459-69. PubMed ID: 2329568
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the oral absorption of some beta-lactams: effect of the alpha-amino side chain group.
Oh DM; Sinko PJ; Amidon GL
J Pharm Sci; 1993 Sep; 82(9):897-900. PubMed ID: 8229687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
